What is the half-life of heparin (unfractionated heparin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Unfractionated Heparin

The half-life of unfractionated heparin is dose-dependent and nonlinear, ranging from approximately 30 minutes after a low-dose IV bolus (25 units/kg) to 60 minutes with a standard bolus (100 units/kg), and up to 150 minutes with high-dose administration (400 units/kg). 1

Pharmacokinetic Characteristics

The complex clearance kinetics of heparin make its half-life highly variable and dependent on the administered dose:

  • At 25 units/kg IV bolus: Half-life is approximately 30 minutes 1
  • At 100 units/kg IV bolus: Half-life extends to approximately 60 minutes 1
  • At 400 units/kg IV bolus: Half-life can reach 150 minutes 1

The FDA-approved labeling confirms this dose-dependent plasma half-life ranges from 0.5 to 2 hours 2.

Mechanism of Nonlinear Clearance

Heparin undergoes biphasic clearance through two distinct mechanisms 1, 2:

  • Rapid saturable mechanism (zero-order): Binding to endothelial cell receptors and macrophages, where heparin is internalized and depolymerized—this pathway predominates at therapeutic doses 1
  • Slower first-order mechanism: Primarily renal clearance, which becomes more relevant at lower doses 1

This dual clearance pathway renders the anticoagulant response nonlinear at therapeutic doses, with both intensity and duration of effect rising disproportionately with increasing dose 1.

Clinical Implications

The dose-dependent half-life has important practical consequences:

  • Immediate onset: Peak plasma concentration and anticoagulant effect occur immediately after IV administration 2
  • Unpredictable duration: The variable half-life contributes to the need for activated partial thromboplastin time (aPTT) monitoring during therapeutic anticoagulation 1
  • Geriatric considerations: Patients over 60 years may have higher plasma levels and longer aPTTs compared to younger patients receiving similar doses 2

Important Caveats

The effective biological half-life increases nonlinearly with dose, meaning doubling the heparin dose more than doubles the duration of anticoagulant effect 1. This nonlinear pharmacokinetic profile explains why heparin requires careful dose titration and monitoring, unlike low-molecular-weight heparins which have predictable, linear pharmacokinetics with half-lives of 3-4 hours regardless of dose 3, 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacology of the low-molecular-weight heparins.

American heart journal, 1998

Research

Pharmacokinetics of low molecular weight heparins.

Acta chirurgica Scandinavica. Supplementum, 1988

Research

Clinical application of enoxaparin.

Expert review of cardiovascular therapy, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.